{
    "clinical_study": {
        "@rank": "25246", 
        "arm_group": [
            {
                "arm_group_label": "Intrathecal Morphine/Sufentanil and PCA", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period."
            }, 
            {
                "arm_group_label": "PCA alone", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine if the administration of a mix of Sufentanil and\n      Morphine in intrathecal is a better analgesia regimen than PCA alone in patient post-VATS."
        }, 
        "brief_title": "RCT Comparing Analgesia Post-VATS With Epimorph VS Placebo", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Thoracic Surgery, Video-assisted", 
            "Postoperative Pain", 
            "Rachianesthesia", 
            "Sufentanil", 
            "Morphine"
        ], 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "detailed_description": {
            "textblock": "This study will compare the need for analgesia (Hydromorphone PCA) of two groups of patients\n      post-VATS. The placebo group will only have a PCA for post-operative analgesia, witch is the\n      standard care for patient post-VATS. The experimental group will have a intrathecal\n      injection of a mix of morphine and sufentanil before the induction of anesthesia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  VATS\n\n          -  ASA 1,2 or 3\n\n          -  Minimum weight of 50 kg\n\n          -  Patient able to consent\n\n        Exclusion Criteria:\n\n          -  Patient refusal\n\n          -  Patient unable to understand PCA\n\n          -  Contraindication to rachianalgesia\n\n          -  Zona\n\n          -  Pregnancy\n\n          -  Over 30 mg of morphine during the last 24 hours\n\n          -  Use of Pregabalin, Gabapentin, Doluxetin, Amitriptyline or NSAI in a context of\n             chronic pain\n\n          -  Severe allergic reaction to morphine, hydromorphone, sufentanil or local anesthetic\n\n          -  Intubation over 1 hour after surgery (unability to use PCA)\n\n          -  High risk of conversion to thoracotomy\n\n          -  Unable to perform rachianalgesia due to technical difficulties"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152514", 
            "org_study_id": "Epimorph for VATS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intrathecal Morphine/Sufentanil and PCA", 
                "intervention_name": "Intrathecal Morphine/Sufentanil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Intrathecal Morphine/Sufentanil and PCA", 
                    "PCA alone"
                ], 
                "intervention_name": "PCA", 
                "intervention_type": "Device", 
                "other_name": "Patient Controlled Analgesia"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Morphine", 
                "Sufentanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "mhmasse.chus@ssss.gouv.qc.ca", 
                "last_name": "Marie-H\u00e9l\u00e8ne Masse", 
                "phone": "819-346-1110", 
                "phone_ext": "14953"
            }, 
            "contact_backup": {
                "email": "sebastien.michaud@usherbrooke.ca", 
                "last_name": "S\u00e9bastien Michaud", 
                "phone": "819-346-1110", 
                "phone_ext": "14403"
            }, 
            "facility": {
                "address": {
                    "city": "Sherbrooke", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "J1H5N4"
                }, 
                "name": "Centre hospitalier universitaire de Sherbrooke"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial Comparing Post-VATS Analgesia Between Patients With an Intrathecal Injection of Morphine and Sufentanil Versus Placebo.", 
        "overall_contact": {
            "email": "mhmasse.chus@ssss.gouv.qc.ca", 
            "last_name": "Marie-H\u00e9l\u00e8ne Masse", 
            "phone": "819-346-1110", 
            "phone_ext": "14953"
        }, 
        "overall_contact_backup": {
            "email": "sebastien.michaud@usherbrooke.ca", 
            "last_name": "S\u00e9bastien Michaud", 
            "phone": "819-346-1110", 
            "phone_ext": "14403"
        }, 
        "overall_official": {
            "affiliation": "Centre Hospitalier Universitaire de Sherbrooke", 
            "last_name": "Yanick Sansoucy", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Canadian Institutes of Health Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The amount of Hydromorphone needed by the patient in the first 24hr after his VATS.", 
            "measure": "Hydromorphone consommation", 
            "safety_issue": "No", 
            "time_frame": "24hr"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152514"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e9 de Sherbrooke", 
            "investigator_full_name": "Yanick Sansoucy", 
            "investigator_title": "Anesthesiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "A VAS will be used.", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "Every 4h x 24hr"
            }, 
            {
                "description": "Including :\nSaturation [Saturation (%) and the need for oxygen (l/min) will be assess to evaluate the incidence of desaturation and hypoventilation in both arms]\nSedation [Sedation will be evaluate with the Riker Sedation Agitation Scale]\nRespiratory rate [To evaluate the incidence of hypoventilation (<8/min) and to compare the average between both arms]", 
                "measure": "Adverse effects of narcotics", 
                "safety_issue": "Yes", 
                "time_frame": "Every 4h x 24hr"
            }, 
            {
                "description": "Including :\nBackache\nHeadache\nLegs strength", 
                "measure": "Adverse reactions associate with rachianesthesia", 
                "safety_issue": "Yes", 
                "time_frame": "24hr"
            }, 
            {
                "description": "Including :\nNausea\nPruritis\nUrinary retention", 
                "measure": "Adverse reactions of narcotics", 
                "safety_issue": "Yes", 
                "time_frame": "24hr"
            }
        ], 
        "source": "Universit\u00e9 de Sherbrooke", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universit\u00e9 de Sherbrooke", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}